METTL3 and hepatocellular carcinoma: We noticed a moderately increased IC50 for sorafenib treatment of METTL3‐knockdown HCCs under normoxic condition (21% O2) (Appendix Fig S2M–O), excluding that the potential molecular mechanism of METTL3‐mediated sorafenib resistance in HCC was mainly caused by hypoxia.